Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
MESO
MESO
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MESO News
Mesoblast Reports Strong Q1 Sales for Ryoncil®
Apr 30 2026
seekingalpha
Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial
Apr 30 2026
Newsfilter
Mesoblast Achieves Patient Recruitment Target in Chronic Low Back Pain Trial
Apr 30 2026
Yahoo Finance
Mesoblast Announces RYONCIL® Net Revenues of $30.3 Million and Reduced Net Operating Cash Expenditure of $4.1 Million for the Quarter
Apr 30 2026
moomoo
Mesoblast Completes Patient Recruitment for Chronic Low Back Pain Trial
Apr 29 2026
NASDAQ.COM
Mesoblast Completes Patient Recruitment for Chronic Low Back Pain Trial
Apr 29 2026
Newsfilter
Mesoblast Completes Patient Recruitment for Chronic Back Pain Trial
Apr 29 2026
Yahoo Finance
Mesoblast Acquires Exclusive CAR Technology License
Apr 15 2026
seekingalpha
Mesoblast Acquires CAR Technology Platform for MSC Products
Apr 15 2026
NASDAQ.COM
Mesoblast Secures Exclusive Global License for CAR Technology
Apr 15 2026
NASDAQ.COM
Mesoblast Secures Exclusive Global License for CAR Technology
Apr 15 2026
Newsfilter
Mesoblast Receives FDA Approval for DMD Clinical Trial
Apr 10 2026
Newsfilter
Mesoblast Unveils Strategy to Double Revenues as Ryoncil Approaches $100M Milestone
Apr 08 2026
Newsfilter
Mesoblast Receives FDA Approval for DMD Study of Ryoncil
Apr 08 2026
seekingalpha
Mesoblast Receives FDA Clearance for DMD Clinical Trial
Apr 08 2026
NASDAQ.COM
Mesoblast Receives FDA Approval for DMD Clinical Trial
Apr 08 2026
Newsfilter
Show More News
